Patents by Inventor Muneto Mogi

Muneto Mogi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12129246
    Abstract: The disclosure relates to a compound of Formula (I): or a pharmaceutically acceptable salt thereof wherein A, Ra to Rd, and R4 to R7, are as described herein, as well as compositions and methods of using such compounds.
    Type: Grant
    Filed: February 28, 2024
    Date of Patent: October 29, 2024
    Assignee: Novartis AG
    Inventors: Daniela Angst, Philippe Bolduc, Matthew William Carson, Atwood Kim Cheung, Véronique Darsigny, Xiang Gao, Viktor Hornak, Keith Jendza, Rajesh Karki, Ajay Kumar Lal, Gang Liu, Justin Yik Ching Mao, Jeffrey M. McKenna, Erik Meredith, Muneto Mogi, Vivek Rauniyar, Liansheng Su, Ritesh Tichkule, Shuangxi Wang, Chun Zhang, Liang Zhao, Rui Zheng
  • Publication number: 20240342174
    Abstract: The present invention provides methods for treating ocular surface pain by administering 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile (compound I). The present invention also provides methods for treating dry eye disease and ocular hyperemia by administering 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile.
    Type: Application
    Filed: March 6, 2024
    Publication date: October 17, 2024
    Inventors: Quintus MEDLEY, Muneto MOGI, Michela MONTECCHI-PALMER, Kalliopi STASI
  • Publication number: 20240336598
    Abstract: The disclosure relates to a compound of Formula (I): or a pharmaceutically acceptable salt thereof wherein A, Ra to Rd, and R4 to R7, are as described herein, as well as compositions and methods of using such compounds.
    Type: Application
    Filed: February 28, 2024
    Publication date: October 10, 2024
    Inventors: Daniela ANGST, Philippe Bolduc, Matthew William Carson, Atwood Kim CHEUNG, Véronique Darsigny, Xiang GAO, Viktor HORNAK, Keith JENDZA, Rajesh KARKI, Ajay Kumar LAL, Gang LIU, Justin Yik Ching MAO, Jeffrey M. McKENNA, Erik MEREDITH, Muneto MOGI, Vivek RAUNIYAR, Liansheng SU, Ritesh TICHKULE, Shuangxi WANG, Chun ZHANG, Liang ZHAO, Rui ZHENG
  • Publication number: 20240247042
    Abstract: Provided herein are novel compounds comprising a GLP-1 compound and a fatty acid or fatty acid derivative, the manufacture of said novel compounds and the use thereof.
    Type: Application
    Filed: April 20, 2022
    Publication date: July 25, 2024
    Inventors: Valerie BEAULIEU, Keith GALYAN, Jinhai GAO, Carol GINSBURG-MORAFF, Pankaj JAIN, Jovita MARCINKEVICIENE, Walter MICHAEL, Muneto MOGI, Martin MARRO, Sejal PATEL, Scott PLUMMER, Alok SINGH, Aimee USERA
  • Publication number: 20230139170
    Abstract: The present invention provides formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile (compound I) and methods for treating ocular surface pain by administering such formulations. The present invention also provides methods for treating dry eye disease and ocular hyperemia by administering formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile.
    Type: Application
    Filed: September 8, 2022
    Publication date: May 4, 2023
    Inventors: Joseph Paul BULLOCK, Chinmay MAHESHWARI, Quintus MEDLEY, Muneto MOGI, Michela MONTECCHI-PALMER, Kalliopi STASI
  • Patent number: 11478480
    Abstract: The present invention provides formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile (compound I) and methods for treating ocular surface pain by administering such formulations. The present invention also provides methods for treating dry eye disease and ocular hyperemia by administering formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile.
    Type: Grant
    Filed: February 13, 2020
    Date of Patent: October 25, 2022
    Assignee: Novartis AG
    Inventors: Joseph Paul Bullock, Chinmay Maheshwari, Quintus Medley, Muneto Mogi, Michela Montecchi-Palmer, Kalliopi Stasi
  • Publication number: 20220193078
    Abstract: The present invention provides methods for treating ocular surface pain by administering 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile (compound I). The present invention also provides methods for treating dry eye disease and ocular hyperemia by administering 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile.
    Type: Application
    Filed: March 8, 2022
    Publication date: June 23, 2022
    Inventors: Quintus MEDLEY, Muneto MOGI, Michela MONTECCHI-PALMER, Kalliopi STASI
  • Publication number: 20220162170
    Abstract: The present disclosure provides polymorphs and formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile (compound I). The present disclosure further provides methods for treating ocular surface pain by administering 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile (compound I). The present invention also provides methods for treating dry eye disease and ocular hyperemia by administering 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile.
    Type: Application
    Filed: February 13, 2020
    Publication date: May 26, 2022
    Inventors: Joseph Paul BULLOCK, Chinmay MAHESHWARI, Quintus MEDLEY, Muneto MOGI, Michela MONTECCHI-PALMER, Gregory MORANDI, Michael MUTZ, Kalliopi STASI, Christopher Stephen TOWLER
  • Patent number: 11234982
    Abstract: The present invention provides methods for treating ocular surface pain by administering 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile (compound I). The present invention also provides methods for treating dry eye disease and ocular hyperemia by administering 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile.
    Type: Grant
    Filed: April 8, 2021
    Date of Patent: February 1, 2022
    Assignee: Novartis AG
    Inventors: Quintus Medley, Muneto Mogi, Michela Montecchi-Palmer, Kalliopi Stasi
  • Publication number: 20210275529
    Abstract: The present invention provides methods for treating ocular surface pain by administering 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile (compound I). The present invention also provides methods for treating dry eye disease and ocular hyperemia by administering 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile.
    Type: Application
    Filed: April 8, 2021
    Publication date: September 9, 2021
    Inventors: Quintus MEDLEY, Muneto MOGI, Michela MONTECCHI-PALMER, Kalliopi STASI
  • Publication number: 20200390767
    Abstract: The present invention provides formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile (compound I) and methods for treating ocular surface pain by administering such formulations. The present invention also provides methods for treating dry eye disease and ocular hyperemia by administering formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile.
    Type: Application
    Filed: August 24, 2020
    Publication date: December 17, 2020
    Inventors: Joseph Paul BULLOCK, Chinmay MAHESHWARI, Quintus MEDLEY, Muneto MOGI, Michela MONTECCHI-PALMER, Kali STASI
  • Publication number: 20200261457
    Abstract: The present invention provides formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile (compound I) and methods for treating ocular surface pain by administering such formulations. The present invention also provides methods for treating dry eye disease and ocular hyperemia by administering formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile.
    Type: Application
    Filed: February 13, 2020
    Publication date: August 20, 2020
    Inventors: Joseph Paul BULLOCK, Chinmay MAHESHWARI, Quintus MEDLEY, Muneto MOGI, Michela MONTECCHI-PALMER, Kali STASI
  • Publication number: 20200261456
    Abstract: The present invention provides methods for treating ocular surface pain by administering 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile (compound I). The present invention also provides methods for treating dry eye disease and ocular hyperemia by administering 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile.
    Type: Application
    Filed: February 13, 2020
    Publication date: August 20, 2020
    Inventors: Quintus MEDLEY, Muneto MOGI, Michela MONTECCHI-PALMER, Kali STASI
  • Patent number: 10550102
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: December 11, 2018
    Date of Patent: February 4, 2020
    Assignee: NOVARTIS AG
    Inventors: Christopher M. Adams, Doug Bevan, Michael Paul Capparelli, Takeru Ehara, Luciana Ferrara, Nan Ji, Erik Meredith, Muneto Mogi, James J. Powers, Ganesh Prasanna, Nello Mainolfi, Mitsunori Kato
  • Patent number: 10537563
    Abstract: The present invention provides in one aspect methods for treating ocular diseases by administering pharmaceutical compositions comprising an inhibitor of colony stimulating factor-1 (CSF-1) receptors. In another aspect, the present invention provides pharmaceutical compositions for treating ocular diseases, the compositions comprising at least one inhibitor of CSF-1R. The inhibitor can also be a selective inhibitor of CSF-1R in certain embodiments.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: January 21, 2020
    Assignee: NOVARTIS AG
    Inventors: Christopher Adams, Muneto Mogi, Stephen Hedrick Poor, Timothy Michael Ramsey, Henry Wu, Qin Zhang
  • Publication number: 20190231765
    Abstract: The present invention provides in one aspect methods for treating ocular diseases by administering pharmaceutical compositions comprising an inhibitor of colony stimulating factor-1 (CSF-1) receptors. In another aspect, the present invention provides pharmaceutical compositions for treating ocular diseases, the compositions comprising at least one inhibitor of CSF-1R. The inhibitor can also be a selective inhibitor of CSF-1R in certain embodiments.
    Type: Application
    Filed: October 13, 2017
    Publication date: August 1, 2019
    Inventors: Christopher ADAMS, Muneto MOGI, Stephen Hedrick POOR, Timothy Michael RAMSEY, Henry WU, Qin ZHANG
  • Publication number: 20190119254
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: December 11, 2018
    Publication date: April 25, 2019
    Inventors: Christopher M. ADAMS, Doug BEVAN, Michael Paul CAPPARELLI, Takeru EHARA, Luciana FERRARA, Nan Ji, Erik MEREDITH, Muneto MOGI, James J. POWERS, Ganesh PRASANNA, Nello MAINOLFI, Mitsunori KATO
  • Patent number: 10208018
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: February 19, 2019
    Assignee: NOVARTIS AG
    Inventors: Christopher M. Adams, Doug Bevan, Michael Paul Capparelli, Takeru Ehara, Luciana Ferrara, Nan Ji, Mitsunori Kato, Nello Mainolfi, Erik Meredith, Muneto Mogi, James J. Powers, Ganesh Prasanna
  • Publication number: 20180153861
    Abstract: The present invention provides a compound of Formula I for use in the treatment, amelioration and/or prevention of diseases and conditions associated with CETP activity, such as atherosclerosis and dyslipidemia, in a subject with high triglyceride level; wherein R1, X1, R7, R5, C, L and p are defined herein. The present invention further provides a combination of pharmacologically active agents for use in the treatment, amelioration and/or prevention of diseases and conditions associated with CETP activity, such as atherosclerosis and dyslipidemia, in a subject with high triglyceride levels.
    Type: Application
    Filed: December 5, 2017
    Publication date: June 7, 2018
    Inventors: Yoshie ARAI, Margaret Elizabeth Brosseau, Jessie Gu, Tomoko Hayashi, Hironobu Mitani, Muneto Mogi, Kazuhiko Nonomura, Ken Yamada
  • Patent number: 9957254
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: May 1, 2018
    Assignee: Novartis AG
    Inventors: Christopher M. Adams, David B. Belanger, Doug Bevan, Philippe Bolduc, Takeru Ehara, Luciana Ferrara, Nan Ji, Mitsunori Kato, Erik Meredith, Muneto Mogi, James J. Powers, Ganesh Prasanna